Q1 2025 EPS Estimates for Alkermes plc Increased by Zacks Research (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities research analysts at Zacks Research increased their Q1 2025 EPS estimates for Alkermes in a research note issued to investors on Tuesday, June 25th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.41 for the quarter, up from their previous forecast of $0.40. The consensus estimate for Alkermes’ current full-year earnings is $2.27 per share. Zacks Research also issued estimates for Alkermes’ FY2025 earnings at $1.90 EPS.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.15). The company had revenue of $350.37 million for the quarter, compared to analyst estimates of $360.26 million. Alkermes had a return on equity of 20.31% and a net margin of 25.17%. The company’s revenue was up 21.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.10) earnings per share.

A number of other research firms also recently weighed in on ALKS. Cantor Fitzgerald lifted their price target on shares of Alkermes from $43.00 to $48.00 and gave the company an “overweight” rating in a research report on Thursday, May 23rd. StockNews.com downgraded shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. TD Cowen initiated coverage on shares of Alkermes in a research report on Monday, June 17th. They issued a “buy” rating and a $34.00 price target for the company. HC Wainwright reiterated a “neutral” rating and issued a $35.00 price target on shares of Alkermes in a research report on Tuesday, June 4th. Finally, Robert W. Baird started coverage on shares of Alkermes in a research report on Tuesday, March 19th. They issued an “outperform” rating and a $37.00 price target for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $36.50.

Alkermes Trading Down 1.1 %

Shares of ALKS stock opened at $24.29 on Friday. The firm has a 50 day moving average price of $24.27 and a two-hundred day moving average price of $26.59. The company has a quick ratio of 2.77, a current ratio of 3.20 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $4.11 billion, a PE ratio of 9.60, a price-to-earnings-growth ratio of 0.49 and a beta of 0.47. Alkermes has a 12-month low of $22.01 and a 12-month high of $33.20.

Institutional Trading of Alkermes

Institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its stake in shares of Alkermes by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,403,195 shares of the company’s stock worth $66,666,000 after purchasing an additional 90,219 shares during the last quarter. S&CO Inc. grew its stake in shares of Alkermes by 13.2% in the fourth quarter. S&CO Inc. now owns 173,145 shares of the company’s stock worth $4,803,000 after purchasing an additional 20,145 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of Alkermes by 521.3% in the fourth quarter. Handelsbanken Fonder AB now owns 175,200 shares of the company’s stock worth $4,860,000 after purchasing an additional 147,000 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Alkermes by 81.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 377,489 shares of the company’s stock worth $10,472,000 after purchasing an additional 169,385 shares during the last quarter. Finally, RTW Investments LP grew its stake in shares of Alkermes by 338.8% in the fourth quarter. RTW Investments LP now owns 3,901,523 shares of the company’s stock worth $108,228,000 after purchasing an additional 3,012,450 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.